06 - 07 September 2021 | London, UK

Achim Doerner

Principal Scientist, Protein Engineering and Antibody Technologies
Merck Healthcare KGaA
Achim Doerner
A biochemist by training, Achim has been working with bispecifics for over a decade, starting with NK cell engaging aptamers, to bispecific antibodies, bispecific ADCs balancing selectivity by avidity to technology development for their effective screening. Further interests lie in concept generation of further complex antibodies such as biparatopics or trispecifics as well as method development, currently towards microfluidics for rapid antibody hit discovery.


No data was found